Skip to main content

About us
Our science
Our Pipeline
Partnering
News & Events
Contact

About us
Our science
Our Pipeline
Partnering
News & Events
Contact

Andreas Busjahn, PhD

Written by wamrhein on August 21, 2026. Posted in Uncategorized.

Previous
Next

Search

Neueste Beiträge

PharmaVoice
A new oral prodrug of the Aβ aggregation modulator GAL-201 shows significantly improved pharmacokinetic profile
Stopping Neurodegeneration at its Source with GAL-101
Fierce Biotech
Innovations in eDREAM, a Phase 2 Clinical Trial in Geographic Atrophy

Neueste Kommentare

No comments to show.

About us
Our science
Our Pipeline
Partnering
News & Events
Contact

Privacy policy

Terms of use

©2026 Galimedix Therapeutics, INC. All rights reserved.